中文Corporate Site
Store HomeProductsCustom SynthesisScientific Resources
LoginRegister
中文Corporate Site
Store HomeProductsCustom SynthesisScientific Resources
LoginRegister

Explore Peptide Science and Life-Science Technologies

Resources on peptide synthesis and drug design, noncanonical amino acids, stable-isotope chemistry and mass-spectrometry analysis.

Curated reading paths

Featured Topics

All topics
17 articles

Peptide Drug Development Stories

Follow the real development paths of Enlicitide, ICOTYDE, and Zilucoplan from screening hits and structural optimization to systemic exposure and clinical translation.

4 articles

mRNA Display: From Library to Candidate

A continuous path from ultra-large libraries, noncanonical amino acids and cyclization to selection trajectories and AI-assisted design.

6 articles

Custom Peptide Synthesis, Purification & Quality Control

A practical path from sequence and synthesis-risk assessment to HPLC purity, salt-form and solubility decisions across custom synthesis, purification and quality control.

10 articles

Noncanonical Amino Acids & Peptide Optimization

Use D-amino acids, N-methylation and conformational constraints to balance activity, stability, permeability, manufacturability and immunogenicity risk.

3 articles

Stable-Isotope Standards, Labeled Materials & Synthesis

A combined path through internal-standard selection and labeling chemistry, from ¹³C/¹⁵N and deuterium strategies to isotope effects, Delta MS and quantitative applications.

3 articles

LC-MS/MS Quantitation & Clinical Applications

Connect small-molecule quantitation, isotope-labeled standards, TDM and immunoassay comparisons into a clinical-MS method strategy.

Published resources

Browse Articles

Advanced search

Noncanonical Amino Acids & Peptide Design · 46 articles

Peptide Drugs & Applications2026/11/15

Peptide Developability: How Should Immunogenicity and Safety Be Evaluated?

Adequate activity and pharmacokinetics do not settle immunogenicity risk. Connect molecular and product-quality evidence, fit-for-purpose ADA assays, and longitudinal clinical outcomes.

Peptide Drugs & Applications2026/11/15

Oral Cyclic Peptide Developability: From Structural Change to Systemic Exposure

Moving one N-methyl group can lower cyclic-peptide permeability, and permeability alone does not ensure oral exposure. Connect structure, in-vitro assays, and pharmacokinetics to the next design decision.

Peptide Drugs & Applications2026/11/15

When a Peptide “Disappears” in Plasma: How Can You Tell Whether It Was Proteolyzed?

A falling parent-peptide LC-MS signal can reflect adsorption, extraction recovery, matrix suppression, or true proteolysis. This article builds the evidence chain from controls and degradation products to the next sequence-design decision.

Peptide Drugs & Applications2026/11/15

How to Improve Peptide Stability: Sequence, Half-Life, and Formulation

Peptide instability may arise from proteolysis, rapid clearance, uncontrolled release, or storage degradation. Locating the failure first determines whether to redesign the sequence, extend half-life, or change the formulation.

Peptide Drugs & Applications2026/10/23

From an mRNA Display Hit to Zilucoplan (3): How Did a Macrocycle Become a Once-Daily Subcutaneous Drug?

Compound 38 already had strong C5-inhibitory activity, but the team still had to maintain sufficient in vivo exposure without compromising target binding. Lipidation and spacer design advanced the optimized molecule toward clinical development and ultimately once-daily subcutaneous zilucoplan.

Peptide Drugs & Applications2026/10/23

From an mRNA Display Hit to Zilucoplan (2): How Were Two Hits Combined into a More Stable Macrocycle?

Compound 1 was more potent but its linear structure exposed plasma-stability problems; Compound 2 was somewhat less potent but already macrocyclic. The team combined features from both to obtain Compound 32, then continued by optimizing the cyclization mode and degradation-prone sites.

Peptide Drugs & Applications2026/10/23

From an mRNA Display Hit to Zilucoplan (1): Two Screening Hits, Two Different Clues

An mRNA display campaign for C5 inhibitors found a more potent linear peptide and a somewhat less potent but directly cyclizable peptide. Each supplied a different clue at the start of zilucoplan discovery.

Peptide Drugs & Applications2026/10/22

Peptide Radiopharmaceuticals: Delivering Radiation Precisely to Tumors

How peptides and peptidomimetics combine target recognition, linkers, chelators, and diagnostic or therapeutic radionuclides for precise tumor delivery.

Page 1 of 6